Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$8.95 CAD
Change Today +0.40 / 4.68%
Volume 1.9K
NVC On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ CM
Frankfurt
As of 3:42 PM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

neovasc inc (NVC) Snapshot

Open
C$8.80
Previous Close
C$8.55
Day High
C$9.54
Day Low
C$8.80
52 Week High
01/30/15 - C$12.75
52 Week Low
08/26/14 - C$4.96
Market Cap
595.4M
Average Volume 10 Days
1.5K
EPS TTM
C$-0.45
Shares Outstanding
66.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEOVASC INC (NVC)

Related News

No related news articles were found.

neovasc inc (NVC) Related Businessweek News

No Related Businessweek News Found

neovasc inc (NVC) Details

Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular products worldwide. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease; the Neovasc Reducer for the treatment of refractory angina; and a line of advanced biological tissue products called Peripatch that are used as components in third-party medical products comprising transcatheter heart valves. The company also provides a range of custom Peripatch products to industry customers for incorporation into their own products, such as transcatheter heart valves and other specialty cardiovascular devices; and consulting and original equipment manufacturing services to other medical device companies. In addition, it offers a line of collagen-based surgical patch products for use in cardiac reconstruction and vascular repair procedures, as well as other surgeries. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.

148 Employees
Last Reported Date: 03/30/15
Founded in 2000

neovasc inc (NVC) Top Compensated Officers

Chief Executive Officer and Non-Independent D...
Total Annual Compensation: C$348.0K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: C$278.5K
Chief Operating Officer and President of Neov...
Total Annual Compensation: C$221.5K
Vice President of Research and Development
Total Annual Compensation: C$181.5K
Vice President of Clinical Affairs
Total Annual Compensation: C$162.0K
Compensation as of Fiscal Year 2014.

neovasc inc (NVC) Key Developments

Neovasc Inc. Reports Unaudited Condensed Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Neovasc Inc. reported unaudited condensed consolidated earnings results for the first quarter ended March 31, 2015. For the period, the company has posted total revenue of CAD 2,860,646 against CAD 3,836,135 a year ago. Operating loss was CAD 6,434,593 against CAD 427,958 a year ago. Loss and comprehensive loss for the period was CAD 6,157,843 or CAD 0.10 basic and diluted per share against CAD 380,072 or CAD 0.01 basic and diluted per share a year ago. Cash used in operating activities was CAD 4,292,336 against CAD 773,164 a year ago. Purchase of property, plant and equipment was CAD 490,138 against CAD 65,862 a year ago.

Neovasc Inc., Annual General Meeting, Jun 16, 2015

Neovasc Inc., Annual General Meeting, Jun 16, 2015., at 08:00 Pacific Standard Time. Location: Suite 2600. Agenda: To receive and consider the audited financial statements of the company for the year ended December 31, 2014 together with the auditor's report thereon; to set the number of directors for the ensuing year at six; to elect directors for the ensuing year; to appoint an auditor for the ensuing year and authorize the directors to approve the remuneration to be paid to the auditor; and to transact such other business as may properly come before the meeting.

Neovasc Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 01:00 PM

Neovasc Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 01:00 PM. Venue: The St. Regis New York, 2 East 55th Street, New York, NY 10022, United States. Speakers: Chris Clark, Chief Financial Officer and Corporate Secretary.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVC:CN C$8.95 CAD +0.40

NVC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Edwards Lifesciences Corp $142.45 USD -1.15
St Jude Medical Inc $73.03 USD -0.60
View Industry Companies
 

Industry Analysis

NVC

Industry Average

Valuation NVC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 37.5x
Price/Book 5.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 33.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOVASC INC, please visit www.neovasc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.